Moderna says it was “shocked” after the FDA declined to review its application for a new mRNA flu vaccine, citing concerns over trial design and standards of care. The decision is being viewed by some experts as a sign of stricter regulatory oversight and a possible shift in how emerging vaccine technologies are evaluated. As research, safety discussions, and approval processes evolve, this development is drawing attention across the medical and public health community.
https://www.vigilantfox.com/p/moderna-shocked-after-fda-scuttles